 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- zavondemstat (TACH101) / Tachyon
Histone methylation changes of H3K9 and H3K36 in PBMCs as pharmacodynamic biomarkers for Zavondemstat (TACH101), a pan-inhibitor of KDM4 histone lysine demethylase (Exhibition Hall) - Sep 7, 2024 - Abstract #EORTCNCIAACR2024EORTC_NCI_AACR_350;
Unless they are part of the media programme, embargoed or not consented, all abstracts will be released on 9 October 2024. All other abstracts will be released on the day of presentation.
- || zavondemstat (TACH101) / Tachyon
Enrollment closed, Enrollment change, Metastases: A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer (clinicaltrials.gov) - Jul 31, 2024
P1, N=30, Active, not recruiting, Sponsor: Tachyon Therapeutics, Inc.
All other abstracts will be released on the day of presentation. Recruiting --> Active, not recruiting | N=70 --> 30
- zavondemstat (TACH101) / Tachyon
A Phase 1 dose escalation study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor for advanced solid tumors (Hall 6 - Poster area) - Jul 24, 2024 - Abstract #ESMO2024ESMO_3699;
- | zavondemstat (TACH101) / Tachyon
Phase classification, Metastases: A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer (clinicaltrials.gov) - Apr 8, 2024
P1, N=70, Recruiting, Sponsor: Tachyon Therapeutics, Inc.
Recruiting --> Active, not recruiting | N=70 --> 30 Phase classification: P1a/1b --> P1
- TACH101 / Tachyon
A Phase 1 dose escalation study of TACH101, a first-in-class KDM4 inhibitor for advanced solid tumors. (LEVEL 2, EXHIBIT HALL D) - Sep 16, 2023 - Abstract #AACRNCIEORTC2023AACR_NCI_EORTC_210;
- ||| zavondemstat (TACH101) / Tachyon
Enrollment open, Trial completion date, Trial primary completion date, Metastases: A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer (clinicaltrials.gov) - Jan 27, 2023
P1a/1b, N=70, Recruiting, Sponsor: Tachyon Therapeutics, Inc.
Phase classification: P1a/1b --> P1 Not yet recruiting --> Recruiting | Trial completion date: Mar 2024 --> Jul 2025 | Trial primary completion date: Jul 2023 --> Jul 2025
- || zavondemstat (TACH101) / Tachyon
Phase classification, Trial primary completion date, Metastases: A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer (clinicaltrials.gov) - Jan 19, 2023
P1a/1b, N=70, Not yet recruiting, Sponsor: Tachyon Therapeutics, Inc.
Not yet recruiting --> Recruiting | Trial completion date: Mar 2024 --> Jul 2025 | Trial primary completion date: Jul 2023 --> Jul 2025 Phase classification: P1 --> P1a/1b | Trial primary completion date: Nov 2023 --> Jul 2023
- TACH101 / Tachyon
Inhibition of cancer stem cells with TACH101, a first-in-class inhibitor of KDM4 histone lysine demethylase. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_5306;
As therapy resistance and metastatic dissemination are grave consequences of CSC activity, TACH101 provides a novel approach to eradicating this population and shows broad applicability as a potential therapeutic agent. Preparations to advance TACH101 into clinical trials are underway.
- TACH101 / Tachyon
TACH101, a first-in-class inhibitor of KDM4 histone lysine demethylase for the treatment of diffuse large B-cell lymphoma (Section 6) - Mar 9, 2022 - Abstract #AACR2022AACR_6173;
The KDM4 inhibitor, TACH101, had compelling activity in preclinical DLBCL models, suggesting that TACH101 could be an effective therapy for DLBCL. Preparations to advance the drug into clinical trials are underway.
- TACH101 / Tachyon
TACH101, a first-in-class pan-inhibitor of KDM4 for treatment of gastrointestinal cancers. (In-Person & On Demand | Level 1, West Hall; Online Only) - Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_523;
Preclinical work on TACH101 KDM4 inhibitor demonstrates compelling data and applicability as a potential therapy for gastrointestinal cancers. Preparations to advance TACH101 into clinical trials are underway.
- | zavondemstat (TACH101) / Tachyon
New P1 trial, Metastases: A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer (clinicaltrials.gov) - Oct 13, 2021
P1, N=70, Not yet recruiting, Sponsor: Tachyon Therapeutics, Inc.
- TACH101 / Tachyon
[VIRTUAL] Identification of pharmacodynamic and sensitivity biomarkers for TACH101, a pan- inhibitor of KDM4 histone lysine demethylase () - Sep 30, 2021 - Abstract #AACRNCIEORTC2021AACR_NCI_EORTC_248;
- TACH101 / Tachyon
[VIRTUAL] TACH101, a first-in-class KDM4 inhibitor for treatment of triple-negative breast cancer () - Jul 22, 2021 - Abstract #ESMO2021ESMO_1599;
Extensive preclinical work on TACH101 KDM4 inhibitor indicates compelling data and applicability as a potential therapy for TNBC. The preparations to advance the drug into clinical trials are underway.
- TACH101 / Tachyon
[VIRTUAL] Pharmacologic characterization of TACH101, a first-in-class KDM4 inhibitor for development as a cancer therapeutic. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_4034;
It did not show inhibition or induction of CYP enzymes suggesting low probability of CYP mediated drug-drug interaction . The exposure from oral administration in rats and dogs was dose proportional and was not significantly affected by food intake in dogs .
- TACH101 / Tachyon
[VIRTUAL] Inhibition of histone lysine demethylases with TACH101, a first-in-class pan-inhibitor of KDM4. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_912;
Extensive preclinical work on TACH101 KDM4 inhibitor shows compelling data and broad applicability as a potential anti-cancer agent . Further evaluation is ongoing to advance the molecule into clinical trials.
- TACH101 / Tachyon
[VIRTUAL] TACH101, a first-in-class pan inhibitor of KDM4 histone lysine demethylases () - Mar 11, 2021 - Abstract #AACR2021AACR_1914;
TACH101 is a potent pan inhibitor of KDM4 that is suggestive of broad potential in cancer treatment. Further preclinical evaluation is ongoing to advance the molecule into clinical trials.